Stockscreener 앱 받기
1.64
0.61%
-0.01
시간 외 거래:
1.66
0.02
+1.22%
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - BỘ NỘI VỤ
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - Markets Financial Content
[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan
Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe
Ensysce (NASDAQ: ENSC) Receives FDA Agreement on PF614 Commercial Manufacturing Approach - Stock Titan
Why Ensysce Biosciences Inc. stock is popular among millennialsJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap - Defense World
Real time social sentiment graph for Ensysce Biosciences Inc.New Guidance & Free Technical Pattern Based Buy Signals - newser.com
Is Ensysce Biosciences Inc. stock trading near support levelsTrade Exit Summary & Proven Capital Preservation Tips - newser.com
What the charts say about Ensysce Biosciences Inc. todayTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
How currency fluctuations impact Ensysce Biosciences Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
What catalysts could drive Ensysce Biosciences Inc. stock higherJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
Ensysce Biosciences Secures $4M Financing for PF614 - The Globe and Mail
Will Ensysce Biosciences Inc. stock remain a Wall Street favorite2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
[8-K] Ensysce Biosciences, Inc. Reports Material Event | ENSC SEC FilingForm 8-K - Stock Titan
Ensysce Biosciences : Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - marketscreener.com
Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan
Ensysce Biosciences, Inc. announced that it has received $2.487 million in funding - MarketScreener
How high can Ensysce Biosciences Inc. stock goProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Why retail investors pile into Ensysce Biosciences Inc. stockJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Ensysce Biosciences Reports Increased R&D Expenses Amid Net Loss - TipRanks
Ensysce Biosciences reports Q3 net loss - MarketScreener
Ensysce Biosciences (NASDAQ: ENSC) begins Phase 3 PF614 trial; Q3 net loss $3.7M - Stock Titan
1.44%
0.91%
자본화:
|
볼륨(24시간):